Kristin Brooks04.28.21
PPD, Inc., a global CRO, and Science 37, developer of the Decentralized Clinical Trial Operating System (DCT OS), entered a collaboration in which PPD will leverage Science 37's DCT SaaS-based technology platform to design, build, test, implement and execute digital trials.
The extended agreement will enable PPD Digital to utilize Science 37's configurable, SaaS-based DCT technology platform to design and implement Remote eConsent, eCOA, eSource and fully decentralized trials, as part of an effort enhance the company’s efficiency and effectiveness in delivering studies for customers.
"Our success with Science 37 has positioned us well to implement and incorporate its technology platform into our clinical trial services model, which is on course with our efforts to maintain a leadership position in the global transition toward decentralized clinical trials," said Niklas Morton, senior vice president, PPD Digital. "Our overall DCT strategy is to offer customers more trial delivery options, particularly in a stepwise fashion where the customer can experience both traditional and digital approaches to sites and patients in the same study. Through our evolving collaboration, we will be able to use the Science 37 platform to provide our customers with a best-in-class service and delivery model."
PPD Digital provides flexible trial solutions across the decentralized spectrum to increase patient access and improve the patient experience to help speed development timelines.
The extended agreement will enable PPD Digital to utilize Science 37's configurable, SaaS-based DCT technology platform to design and implement Remote eConsent, eCOA, eSource and fully decentralized trials, as part of an effort enhance the company’s efficiency and effectiveness in delivering studies for customers.
"Our success with Science 37 has positioned us well to implement and incorporate its technology platform into our clinical trial services model, which is on course with our efforts to maintain a leadership position in the global transition toward decentralized clinical trials," said Niklas Morton, senior vice president, PPD Digital. "Our overall DCT strategy is to offer customers more trial delivery options, particularly in a stepwise fashion where the customer can experience both traditional and digital approaches to sites and patients in the same study. Through our evolving collaboration, we will be able to use the Science 37 platform to provide our customers with a best-in-class service and delivery model."
PPD Digital provides flexible trial solutions across the decentralized spectrum to increase patient access and improve the patient experience to help speed development timelines.
